| Today’s Big NewsMar 27, 2024 |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
| By James Waldron Blackstone Life Sciences is making a $750 million bet on Moderna’s influenza vaccine program as part of the investment platform’s push to “support innovative mRNA technology.” |
|
|
|
By Nick Paul Taylor Altimmune has been beaten by hepatitis B. The drug candidate, which Altimmune was preparing for partnering, failed to meet the bar for further development in a phase 2 study, prompting the biotech to stop development and focus on its GLP-1/glucagon dual receptor agonist. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
By James Waldron With the search for a partner for an approved stem cell therapy coming up short, cash-strapped Gamida Cell has accepted that the only way to remain a going concern is to allow its principal lender to acquire the company. |
|
Thursday, April 11, 2024 | 11am ET / 8am PT As clinical trials increase in complexity, drug developers face growing pressure to deliver on-time, on-budget studies. FSP partnerships have emerged as a pivotal strategy to help address current challenges. Join us to learn moreas we explore the findings of The 2024 FSP Trends Report from the PPD clinical research business of Thermo Fisher Scientific. Sign up now! 
|
|
By Gabrielle Masson Though Pfizer has terminated one of two phase 3 trials assessing a monoclonal antibody designed to treat sickle cell disease, the New York-based Pharma still plans on securing a market approval for the asset by 2026. |
By Gabrielle Masson Transparent mischief. Malfeasances. And now—a hands-down victory. Nymox CEO Paul Averback, M.D., used all these descriptors in a March 27 release announcing an end to Bahamas litigation brought against the biotech by several former employees. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Conor Hale The main difference in the design of the Evolut FX+ is the addition of larger gaps that make it easier for a patient to undergo coronary procedures in the future. |
By Fraiser Kansteiner As pharma firms increasingly favor distribution pacts rather than relying on local subsidiaries to market their drugs, French major Sanofi has enlisted local companies to enhance the profile of its medicines across South and East Asia. |
By Paige Minemyer The NCAA basketball tournament gets underway today, and the Fierce Healthcare team is gearing up yet again for our annual #FierceMadness competition. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the European biotech investment landscape. Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. |
|
|---|
|
|
|
Thursday, March 28, 2024 | 11am ET / 8am PT Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. Join us to learn more about the top challenges cell therapy developers are facing. We explore the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. Register now. 
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
